AKESO's stock price surged 5.32% during the morning trading session, marking a significant rebound for the biopharmaceutical company.

The upward movement represents a recovery following a previous sell-off triggered by news from partner Summit Therapeutics regarding an interim analysis of the global Phase III Harmoni-3 trial for ivonescimab. While the squamous NSCLC cohort initially failed to meet pre-specified statistical significance at the interim stage, market participants are now reassessing the implications, recognizing that this outcome does not constitute a clinical failure and that the study will proceed to its final analysis.

Institutional commentary has supported the rebound, with analysis suggesting that failing the stringent interim criteria does not preclude the drug from potentially outperforming Keytruda in the final analysis later in 2026. This renewed confidence, based on experience from related trials, is driving the stock's recovery from its recent declines.